Design and synthesis of peptidic partial agonists of human neuromedin U receptor 1 with enhanced serum stability.

[1]  B. Holst,et al.  Synthesis and in Vitro Evaluation of Stabilized and Selective Neuromedin U-1 Receptor Agonists. , 2018, ACS medicinal chemistry letters.

[2]  J. Noguchi,et al.  Differential effects of selective agonists of neuromedin U1 and U2 receptors in obese and diabetic mice , 2018, British journal of pharmacology.

[3]  K. Mori,et al.  Discovery of a Human Neuromedin U Receptor 1-Selective Hexapeptide Agonist with Enhanced Serum Stability. , 2017, Journal of medicinal chemistry.

[4]  Y. Hayashi,et al.  Identification of a degrading enzyme in human serum that hydrolyzes a C‐terminal core sequence of neuromedin U , 2016, Biopolymers.

[5]  K. Mori,et al.  Discovery of potent hexapeptide agonists to human neuromedin u receptor 1 and identification of their serum metabolites. , 2015, ACS medicinal chemistry letters.

[6]  K. Mori,et al.  Discovery of selective hexapeptide agonists to human neuromedin U receptors types 1 and 2. , 2014, Journal of medicinal chemistry.

[7]  A. Peier,et al.  Development of a neuromedin U–human serum albumin conjugate as a long‐acting candidate for the treatment of obesity and diabetes. Comparison with the PEGylated peptide , 2014, Journal of peptide science : an official publication of the European Peptide Society.

[8]  A. Peier,et al.  PEGylation of Neuromedin U yields a promising candidate for the treatment of obesity and diabetes. , 2012, Bioorganic & medicinal chemistry.

[9]  E. Di Cera,et al.  Crystal Structure of Thrombin Bound to the Uncleaved Extracellular Fragment of PAR1* , 2010, The Journal of Biological Chemistry.

[10]  John T. Williams,et al.  Buprenorphine Is a Weak Partial Agonist That Inhibits Opioid Receptor Desensitization , 2009, The Journal of Neuroscience.

[11]  E. Di Cera,et al.  Crystal structures of murine thrombin in complex with the extracellular fragments of murine protease-activated receptors PAR3 and PAR4 , 2007, Proceedings of the National Academy of Sciences.

[12]  C. Rück,et al.  A Stepped Care Strategy Using Buprenorphine and Methadone Versus Conventional Methadone Maintenance in Heroin Dependence: A Randomized Controlled Trial , 2007 .

[13]  Y. Kanai,et al.  Central actions of neuromedin U via corticotropin-releasing hormone. , 2003, Biochemical and biophysical research communications.

[14]  J. Kane,et al.  Efficacy and safety of aripiprazole and haloperidol versus placebo in patients with schizophrenia and schizoaffective disorder. , 2002, The Journal of clinical psychiatry.

[15]  B. Borowsky,et al.  Identification and Characterization of Two Neuromedin U Receptors Differentially Expressed in Peripheral Tissues and the Central Nervous System* , 2000, The Journal of Biological Chemistry.

[16]  M. Nakazato,et al.  Central effects of neuromedin U in the regulation of energy homeostasis. , 2000, Biochemical and biophysical research communications.

[17]  M. Nakazato,et al.  Purification and identification of neuromedin U as an endogenous ligand for an orphan receptor GPR66 (FM3). , 2000, Biochemical and biophysical research communications.

[18]  O. Nishimura,et al.  Identification of Neuromedin U as the Cognate Ligand of the Orphan G Protein-coupled Receptor FM-3* , 2000, The Journal of Biological Chemistry.

[19]  N. Minamino,et al.  Neuromedin U-8 and U-25: novel uterus stimulating and hypertensive peptides identified in porcine spinal cord. , 1985, Biochemical and biophysical research communications.